Literature DB >> 7680861

A peptide derived from an autoantibody can stimulate T cells in the (NZB x NZW)F1 mouse model of systemic lupus erythematosus.

F M Ebling1, B P Tsao, R R Singh, E Sercarz, B H Hahn.   

Abstract

OBJECTIVE: To assess the ability of peptides derived from anti-DNA to stimulate syngeneic T lymphocytes and influence lupus in (NZB x NZW)F1 (NZB/W) mice.
METHODS: We synthesized (by Geysen pin method) overlapping 12-mer peptides recapitulating the amino acid sequence of the VH region of a nephritogenic monoclonal IgG2a anti-DNA antibody (A6.1) from an NZB/W mouse. Splenic T cells were cultured with the peptides; multiple experiments assayed 12-mer and 16-mer peptides which contained a triple-base motif (KFKGK). We immunized 20-week-old NZB/W mice with the 12-mer and evaluated them for evidence of nephritis and for quantities of antibodies in plasma and glomeruli.
RESULTS: Three clusters of peptides caused proliferation of spleen cells from young, nonimmunized mice. Both the 12-mer FYNQKFKGKATL and the 16-mer GDTFYNQKFKGKATLT peptides stimulated purified T cells. The KXKXK motif occurs in 15% of murine Ig VH (NBRF protein database), compared with 100% (6 of 6) of NZB/W anti-DNA monoclonal antibody. Immunization with the 12-mer peptide increased plasma levels of IgG, anti-DNA, and immune complexes, and levels of anti-DNA in glomeruli; nephritis was accelerated.
CONCLUSION: NZB/W anti-DNA contain peptide sequences in their VH regions that stimulate self-T cells. At least one motif is frequent in NZB/W anti-DNA. If some activated T cells provide help, this mechanism may contribute to sustained up-regulation of autoantibodies in murine lupus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680861     DOI: 10.1002/art.1780360311

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus.

Authors:  Defu Zeng; Yinping Liu; Stephane Sidobre; Mitchell Kronenberg; Samuel Strober
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

3.  Activation of diverse repertoires of autoreactive T cells enhances the loss of anti-dsDNA B cell tolerance.

Authors:  Brian W Busser; Brigette S Adair; Jan Erikson; Terri M Laufer
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

4.  Idiotype usage by polyclonally activated B cells in experimental autoimmunity and infection.

Authors:  M Sutmuller; J J Baelde; M P Madaio; J A Bruijn; E De Heer
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

5.  Natural antibodies that react with V-region peptide epitopes of DNA-binding antibodies are made by mice with systemic lupus erythematosus as disease develops.

Authors:  F J Ward; J E Knies; C Cunningham; W J Harris; N A Staines
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

6.  In vivo induction of IgG anti-DNA antibody by autoreactive mixed haplotype A beta z/A alpha d MHC class II molecule-specific CD4+ T-cell clones.

Authors:  M Tokushima; S Koarada; S Hirose; Y Gotoh; H Nishimura; T Shirai; K Miyake; M Kimoto
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

7.  T-cell tolerance induction is normal in the (NZB x NZW)F1 murine model of systemic lupus erythematosus.

Authors:  J Wither; B Vukusic
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

8.  A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice.

Authors:  C Jouanne; S Avrameas; B Payelle-Brogard
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

9.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 10.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice.

Authors:  Brian J Skaggs; Ram Pyare Singh; Bevra H Hahn
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.